Notably, the DEGs-associated with the estrogen signaling pathway, including several heat shock proteins (HSPA6, HSPA7, HSP90AA2P, and HSP90AA1) and the oncogene, HRAS, were all downregulated, suggesting that simultaneous treatment with EPA and bortezomib might inhibit the estrogen signaling pathway in MM cells. The gene discussed is HSP90AA1; the disease is Miyoshi myopathy.